OPKO Health (LTS:0KCS) 10-Year ROIIC % : 18.98% (As of Dec. 2025)


LTS:0KCS OPKO Health Inc LTS:0KCS
57 GF Score
Price $1.35
GF Value $1.06
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is OPKO Health 10-Year ROIIC %?

OPKO Health LTS:0KCS -2.88% 57 10-Year ROIIC % is 18.98 as of Dec. 2025. GuruFocus rates LTS:0KCS with a GF Score™ of 57/100 and a GF Value™ of $1.06 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 178 Medical Diagnostics & Research companies, OPKO Health ranks better than 79.78% on this metric.

10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year. OPKO Health's 10-Year ROIIC % for the quarter that ended in Dec. 2025 was 18.98%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for OPKO Health's 10-Year ROIIC % or its related term are showing as below:

LTS:0KCS's 10-Year ROIIC % is ranked better than
79.78% of 178 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.52 vs LTS:0KCS: 18.98

OPKO Health  (LTS:0KCS) 10-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


OPKO Health 10-Year ROIIC % Related Terms


OPKO Health 10-Year ROIIC % Historical Data

* Premium members only.

The historical data trend for OPKO Health's 10-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OPKO Health 10-Year ROIIC % Chart

OPKO Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
10-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.52 -10.85 -13.81 -32.91 18.98

OPKO Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
10-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 18.98 0.00

LTS:0KCS vs PSNL, CDNA, CSTL: 10-Year ROIIC % Comparison

For the Diagnostics & Research subindustry, OPKO Health's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OPKO Health 10-Year ROIIC % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, OPKO Health's 10-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where OPKO Health's 10-Year ROIIC % falls into.


LTS:0KCS
57GF Score
OPKO Health Inc LTS:0KCS
10-Year ROIIC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OPKO Health 10-Year ROIIC % Calculation

OPKO Health's 10-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:

10-Year ROIIC %=10-Year Incremental Net Operating Profit After Taxes (NOPAT)**/10-Year Incremental Invested Capital**
=( -204.7290765 (Dec. 2025) - -16.4718853 (Dec. 2015) )/( 1478.725 (Dec. 2025) - 2470.526 (Dec. 2015) )
=-188.2571912/-991.801
=18.98%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.

Frequently Asked Questions Learn more about 10-Year ROIIC % →
What does a 10-Year ROIIC % of 18.98 mean?
OPKO Health (LTS:0KCS) has a 10-Year ROIIC % of 18.98 as of Dec. 2025. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on OPKO Health and its competitors. According to the industry distribution chart, OPKO Health ranks #36 out of 178 companies in the Medical Diagnostics & Research industry, placing it in the top 20.2%.
Is OPKO Health's 10-Year ROIIC % too high?
OPKO Health's current 10-Year ROIIC % is 18.98. The Medical Diagnostics & Research industry median 10-Year ROIIC % is 1.52. OPKO Health's value of 18.98 is 1148.7% above this industry median. Based on the distribution chart, OPKO Health ranks #36 out of 178 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, OPKO Health has a GF Score™ of 57/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OPKO Health's 10-Year ROIIC % compare to PSNL and CDNA?
According to the Medical Diagnostics & Research industry distribution chart, OPKO Health ranks #36 out of 178 companies for 10-Year ROIIC %. This places OPKO Health in the top 20% of its industry — outperforming the majority of peers. The industry median 10-Year ROIIC % is 1.52. OPKO Health's value of 18.98 is 1148.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year ROIIC % for a Medical Diagnostics & Research company?
The median 10-Year ROIIC % among Medical Diagnostics & Research companies is 1.52, based on 178 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OPKO Health's current 10-Year ROIIC % of 18.98 is 1148.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year ROIIC % mean?
A high 10-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on OPKO Health and its competitors. For the Medical Diagnostics & Research industry, the median 10-Year ROIIC % is 1.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OPKO Health's current 10-Year ROIIC % is 18.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OPKO Health stock overvalued right now?
Based on GuruFocus' analysis, OPKO Health (LTS:0KCS) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.06, compared to a current price of $1.35 — trading 27.4% above its estimated fair value. The current 10-Year ROIIC % is 18.98 and 1148.7% above the Medical Diagnostics & Research industry median of 1.52. OPKO Health's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year ROIIC % calculated?
10-Year ROIIC % is calculated from a company's financial statements. For OPKO Health (LTS:0KCS), the current 10-Year ROIIC % is 18.98 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OPKO Health (LTS:0KCS) Overvalued in 2026?

Based on GuruFocus' analysis, OPKO Health stock appears to be overvalued. The current stock price of $1.35 is trading 27.4% above its estimated GF Value™ of $1.06. GuruFocus considers OPKO Health to be Modestly Overvalued.

Key valuation signals for LTS:0KCS:

  • 10-Year ROIIC %: 18.98
  • GF Value™: $1.06 vs. price of $1.35 (27.4% above fair value)
  • GF Score™: 57/100 with 4 warning signs
  • Industry Position: 1148.7% above the Medical Diagnostics & Research median (#36 of 178)

No single metric tells the full story. See the LTS:0KCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


OPKO Health Business Description

Address 4400 Biscayne Boulevard, Miami, FL, USA, 33137
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
57GF Score

Get the complete analysis for LTS:0KCS

10-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.35
Price
$1.06
GF Value